Mostrando 24,301 - 24,320 Resultados de 24,879 Para Buscar '".eu"', tiempo de consulta: 0.25s Limitar resultados
  1. 24301
    “…Two questionnaires – the Health Literacy Survey European Questionnaire (HLS-EU-Q16) and the eHealth Literacy Scale (eHEALS) – and questions about self-perceived health and Internet use were distributed in Swedish and Arabic. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 24302
    “…Cefiderocol (CFDC), a siderophore cephalosporin approved in US and EU, is active in vitro against carbapenem-resistant Gram-negative bacteria including Burkholderia spp. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  3. 24303
    “…The vaccine is also licensed in ages 12 months and older in EU and other countries. METHODS: A phase IIIb study (NCT04084769) was conducted to evaluate the persistence of immune response in adults and adolescents primed 3-6 years earlier with either MenACYW-TT or MCV4-CRM (Menveo(®)) and, safety and immunogenicity of MenACYW-TT when administered as a booster dose with or without concomitant administration with MenB vaccines (Bexsero(®) and Trumenba(®)). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  4. 24304
    “…METHODS: We estimated the country specific and overall annual costs of varicella in absence of UVV in 31 European countries (27 EU countries, plus Iceland, Norway, Switzerland and the United Kingdom). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  5. 24305
  6. 24306
    “…To reveal the regulation mechanisms of YBX1, we conducted differentially expression analysis, alternative splicing (AS) analysis, enrichment analysis, and 5-EU staining using DESeq2, rMATs, clusterProfiler, and immunofluorescence technique, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 24307
    por Benamirouche, R.
    Publicado 2022
    “…RÉSULTATS: On a remarqué la présence d'une forte asymétrie d'information qui pouvait entacher les études épidémiologiques d'erreurs et d'incertitudes eu égard à la propagation du virus. Il était nécessaire de donner des recommandations pour légiférer des textes et prendre des mesures adéquates pour rendre obligatoire la déclaration des cas de contamination par les établissements de santé publique ou privés et ainsi proposer notre approche pour un SIH adapté aux crises sanitaires avec un alignement stratégique du SIH pour toute réforme hospitalière. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  8. 24308
    “…Extending vaccination coverage in students, complemented by regular testing with good adherence, are essential steps to keep schools open when highly transmissible variants are circulating. FUNDING: EU Framework Programme for Research and Innovation Horizon 2020, Horizon Europe Framework Programme, Agence Nationale de la Recherche, ANRS–Maladies Infectieuses Émergentes.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  9. 24309
    por Hannerz, Harald, Flyvholm, Mari-Ann
    Publicado 2022
    “…BACKGROUND: The cost of mental ill health in the EU-28 nations has been estimated at approximately 4.1% of the total gross domestic products (GDP). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 24310
    “…If, on the other hand, the trial demonstrates an increased risk of gastrointestinal bleeding events in patients after PPI withdrawal, this could create a rationale for a more liberal, prophylactic PPI treatment in patients with liver cirrhosis. TRIAL REGISTRATION: EU clinical trials register EudraCT 2019-005008-16 (registered December 27, 2019). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 24311
    “…The trial was registered with the European Clinical Trials Database (#EudraCT 2010-021219-17) on July 1, 2011 (clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/ES) and with ClinicalTrials.gov (#NCT01433497) on September 14, 2011 (clinicaltrials.gov/ct2/show/NCT01433497). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  12. 24312
    “…Les patients ayant un questionnaire positif ont eu un bilan comprenant un bilan neuropsychologique, des échelles de dépistage de l’anxiété, la dépression, la fatigue et du syndrome de stress post traumatique, un examen clinique neurologique et une IRM cérébrale. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  13. 24313
  14. 24314
    “…We aimed to map the current clinical practice for thromboprophylaxis management in patients with CS across reference centers (RCs) of the European Reference Network on Rare Endocrine Conditions (Endo-ERN), which are endorsed specifically for the diagnosis and treatment of CS. Using the EU survey tool, a primary screening survey, and subsequently a secondary, more in-depth survey were developed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 24315
    “…All CFTR modulators have been licensed in the US as orphan drugs, but in the EU the orphan status for LUM/IVA was not confirmed at the time of marketing authorization as results from the pivotal trial were not considered clinically significant. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 24316
    “…Unpublished studies and gray literature were searched in trial registers (ACTRN, ChiCTR, ChiCtr, CTRI, DRKS, EUCTR, IRCT, ISRCTN, JPRN UMIN, ClinicalTrials.gov, NTR, TCTR) and databases (OpenGrey.eu, NARCIS.nl, DART-Europe.org, OATD.org). Randomized controlled trials (RCTs) and non-randomized controlled clinical trials (CCTs) were eligible when investigating the clinical effectiveness of ESWT for chronic mid-AT or chronic ins-AT. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  17. 24317
    “…Treatment tolerability was good and consistent with previous CsA 0.1% CE clinical studies. TRIAL REGISTRATION: EU PAS register number: EUPAS 22376. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-022-00487-x.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  18. 24318
    “…INTRODUCTION: The aim of this sub-study was to evaluate injection success of patients with rheumatoid arthritis (RA) and their caregivers administering the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada(®)/Amsparity(®)/Xilbrilada(®)) by prefilled pen (PFP) during the open-label treatment period in year two (weeks 52–78) of a phase 3 multinational, double-blind, clinical study (NCT02480153) comparing ADL-PF and reference ADL (Humira(®)) sourced from the EU. METHODS: This sub-study included adult patients with active RA not adequately controlled by methotrexate. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 24319
    por Lablanche, O., Fraison, E.
    Publicado 2022
    “…CONCLUSION: L’arrêt des soins pendant la pandémie de COVID-19 a eu un impact psychologique important sur les femmes avec une augmentation du stress et a minima de l’anxiété. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 24320
Herramientas de búsqueda: RSS